ARBUTUS BIOPHARMA CORPORATION — Earnings
Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR
Next earnings (estimated): Wed, April 1, 2026 — 32 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | $1M | ↓-33.2% | — | — | — |
| 2025-09-30 | $529K | ↓-60.5% | $-8M | ↑+60.7% | -1636.9% |
| 2025-06-30 | $11M | ↑+522.2% | $3M | ↑+112.7% | 13.9% |
| 2025-03-31 | $2M | ↑+15.1% | $-25M | ↓-37.2% | -1456.9% |
| 2024-12-31 | $2M | ↓-26.6% | — | — | — |
| 2024-09-30 | $1M | ↓-71.3% | $-20M | ↑+1.9% | -1601.2% |
| 2024-06-30 | $2M | ↓-62.9% | $-20M | ↓-15.8% | -1250.5% |
| 2024-03-31 | $2M | ↓-77.1% | $-18M | ↓-9.4% | -1263.9% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2025 (Q4)
Revenue
$1M
↓-33.2% -$523K YoY
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Go deeper
ABUS Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyABUS Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics